Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis | NEJM
Mind the gap – Managing tuberculosis across the disease spectrum - eBioMedicine
Assessment of tuberculosis disease activity in people infected with Mycobacterium tuberculosis and living with HIV: A longitudinal cohort study - eClinicalMedicine
New agents for the treatment of drug-resistant Mycobacterium tuberculosis - ScienceDirect
Phosphoenolpyruvate depletion mediates both growth arrest and drug tolerance of Mycobacterium tuberculosis in hypoxia | PNAS
Cepheid | Cepheid | TB Drug-Resistance Testing | Xpert MTB-XDR
Role of empiric treatment in hospitalized patients with Xpert MTB/RIF-negative presumptive pulmonary tuberculosis: A prospective cohort study - International Journal of Infectious Diseases
Microorganisms | Free Full-Text | Diabetes-Associated Susceptibility to Tuberculosis: Contribution of Hyperglycemia vs. Dyslipidemia
Xpert MTB/RIF Ultra Is Highly Sensitive for the Diagnosis of Tuberculosis Lymphadenitis in a High-HIV Setting | Journal of Clinical Microbiology
![PDF] Nitric Oxide in the Pathogenesis and Treatment of Tuberculosis | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/4b2748c6b14c22d792915b1e9fc3db2be946ae59/3-Figure2-1.png "PDF] Nitric Oxide in the Pathogenesis and Treatment of Tuberculosis | Semantic Scholar")
PDF] Nitric Oxide in the Pathogenesis and Treatment of Tuberculosis | Semantic Scholar
Estimated viable Mtb in sputum during the first 56 days of treatment... | Download Scientific Diagram
Reduced treatment delays for people with drug-resistant TB and HIV co-infection through decentralised care and rapid Xpert MTB/RIF test | aidsmap
Figure 5 - Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia - Volume 22, Number 3—March 2016 - Emerging Infectious Diseases journal - CDC
Tuberculosis: Past, present and future of the treatment and drug discovery research - ScienceDirect
Early tuberculosis treatment monitoring by Xpert® MTB/RIF | European Respiratory Society
Comprehensive gene profiling, molecular tumor board (mtb) and artificial intelligence in the diagnosis and treatment of patients with rare adult cancers – EJP RD – European Joint Programme on Rare Diseases
Estimated clinical impact of the Xpert MTB/RIF Ultra cartridge for diagnosis of pulmonary tuberculosis: A modeling study | PLOS Medicine
Juliana Furtado Gets the Lower-link VPP Treatment - Mountain Bike Press Release - Vital MTB
Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study | PLOS ONE
Ultrasound in managing extrapulmonary tuberculosis: a randomized controlled two-center study | BMC Infectious Diseases | Full Text
Frontiers | Molecular Diagnosis of Drug-Resistant Tuberculosis; A Literature Review
Multidrug-resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis – TB DIAH
Can the GeneXpert MTB/XDR deliver on the promise of expanded, near-patient tuberculosis drug-susceptibility testing? - The Lancet Infectious Diseases
Prevalence of Mycobacterium tuberculosis (Rifampicin-Resistant MTB) and Associated Risk Actors Among Pulmonary Presumptive TB Patients in Eastern Amhara, Ethiopia: 2015–2019 | SpringerLink
The value of lateral flow urine lipoarabinomannan assay and empirical treatment in Xpert MTB/RIF ultra negative patients with presumptive TB: a prospective cohort study | Scientific Reports
Neutrophil-specific biomarkers as proxy for... | Documents | Open Research Africa
